Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

    Funding for NIAMS Clinical Trial Implementation with simplified review changes; open for UG3/UH3 clinical trials under this Cooperative Agreement.

    OverviewSimilar Grants
    OverviewSimilar Grants

    Funder: National Institutes of Health

    Due Dates: March 4, 2027 (Application)

    Funding Amounts: UG3: up to $250,000 in direct costs for up to one year; UH3: no budget cap, up to five years

    Summary: Supports implementation of investigator-initiated interventional clinical trials addressing arthritis, musculoskeletal, and skin diseases and disorders.

    Key Information: Trial planning must be complete before applying; transition to UH3 depends on achieving NIAMS-approved UG3 milestones.


    Description

    The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports investigator-initiated, single- or multi-site interventional clinical trials of all phases through this milestone-driven cooperative agreement. Trials should be hypothesis-driven and have potential for high clinical impact within the NIAMS mission. Supported work includes prevention and treatment trials, evaluations of novel therapeutic approaches, and interventions to increase preventive health behaviors.

    Applicants must have completed advance preparation, including trial design, a protocol synopsis, and a data analysis plan. The UG3 phase supports final start-up activities such as site agreements, staffing, and approvals. The UH3 phase supports enrollment and trial execution. This mechanism is intended for larger, more complex, or higher-risk trials, with substantial NIH scientific or programmatic involvement.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.